Valuation
- Market cap
- 1,787,915,000
- Revenue TTM
- $79,950,000
- Net income TTM
- $-4,600,000
- P/E (trailing)
- 42.15
- P/E (forward)
- 41.33
- Profit margin
- -5.75%
- Debt to equity
- 0.27
Trading
- Volume
- 389,000
- Avg volume
- 583,720
- Day's range
- $61.01 – $63.38
- Shares out
- 28,842,000
- Stochastic %K
- 32%
- Beta
- 0.89
- Analysts
- Strong Buy
- Price target
- $71.90
Company profile
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate syn...
Show more
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 847 787 7361
- Website
- https://www.etonpharma.com
- Address
- 21925 W. Field Parkway, Suite 235, Deer Park, United States
Latest news
No headlines yet.